Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lupin, Glenmark and Orchid receive FDA OK for levetiracetam

This article was originally published in Scrip

Executive Summary

LupinPharmaceuticals, Glenmark Genericsand Orchid Chemicals and Pharmaceuticals, have received approval from the US FDA for levetiracetam 250mg, 500mg and 750mg tablets, generic versions of UCB Pharmaceuticals' anti-epileptic, Keppra tablets. Lupin has received approval for levetiracetam 1,000mg tablets and the company has begun commercial shipments of its products. Glenmark has commenced marketing and distribution of its generic versions in the US – it has a partnership with Invagen Pharmaceuticals for the product, under which Glenmark will exclusively market and distribute the product while Invagen is responsible for its manufacture and supply. Levetiracetam tablets had sales of about $1.2 billion in the 12 months ended September 2008. Glenmark now has 38 generic products authorised for distribution in the US, while Orchid's cumulative ANDA approval count now stands at 30.

You may also be interested in...

APAC Cancer Preparedness Varied, Late Diagnosis A Key Challenge

A new report on the preparedness of 10 APAC nations to tackle a mounting cancer burden identifies gaps that need to be addressed, saying that a focus on prevention and early diagnosis could help, while also touching on issues around regional drug availability.

Asia Deal Watch: Cipla’s Latest Diabetes Partner In India Is Boehringer Ingelheim

Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.

Opdivo Secures India Patent, Fends Off Multi-Party Opposition

India clears Opdivo patent, turning down pre-grant representations from four opposing parties including Dr Reddy's. The patent office rejected the opponents' arguments including those around obviousness and "inherent anticipation."

Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts